FDA Fast-Tracks Psychedelic Therapy for Veterans' PTSD

Veterans suffering from PTSD and depression may soon have access to a treatment that reduced their symptoms by up to 90% in just one month.

President Trump signed an executive order Saturday directing the FDA to expedite review of psychedelic therapies already designated as breakthrough drugs. The move focuses on ibogaine, a plant-based treatment that showed remarkable results in recent clinical trials.

A 2024 Stanford University study tested ibogaine on 30 special operations veterans with traumatic brain injuries. Within one month, participants experienced an 80 to 90% reduction in symptoms of depression and anxiety.

The timing couldn't be more critical. More than 6,000 veterans die by suicide every year, a rate that has remained stubbornly high since 2001. In fact, more service members have been lost to suicide than combat in the past two decades.

The executive order removes bureaucratic hurdles and improves data sharing between the FDA and the Department of Veterans Affairs. It also creates a pathway for ibogaine to be administered to severely ill patients under the right to try law.

Both federal and state governments are investing heavily in the research. Texas committed $50 million to ibogaine research, and the federal government just approved a matching $50 million investment.

Ibogaine comes from a rainforest shrub used for centuries in Central Africa. During treatment, it allows patients to process traumatic memories while experiencing therapeutic visions that help address PTSD-related psychological content.

The Ripple Effect

This breakthrough extends far beyond veterans. More than 14 million Americans live with serious mental illness, and one in four adults experiences a diagnosable disorder each year. Suicide rates have risen more than 30% over the past two decades.

Millions of Americans with depression, PTSD, and addiction don't respond to existing treatments. These psychedelic therapies offer hope for people who have exhausted conventional options.

The order also benefits from an unexpected champion: podcaster Joe Rogan invited advocates onto his show, giving millions of listeners the chance to hear real stories of life-changing experiences with ibogaine treatment.

After years of research hitting bureaucratic roadblocks, these promising treatments are finally getting the accelerated pathway they deserve.